Related content

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Separated into Two Subgroups Associated with Survival by BCR-ABL Fluorescence in situ Hybridization of Segmented Cell Nuclei: Report from a Single Institution

By  

Acta Haematologica, Vol. 136, Iss. 3, 2016-08 ,pp. : 157-166

Karger

Access to resources Recommend Favorite

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

PEDIATRICS INTERNATIONAL, Vol. 60, Iss. 1, 2018-01 ,pp. : 85-87

John Wiley & Sons Inc

Access to resources Recommend Favorite